REG - Kanabo Group PLC - Appointment of Auditor

KanaboAnnouncement

07/03/2023 12:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230307:nRSG1764Sa&default-theme=true

RNS Number : 1764S  Kanabo Group PLC  07 March 2023

7 March 2023

 

Kanabo Group plc

("Kanabo", the "Group" or the "Company")

 

Appointment of Auditor

 

Kanabo Group plc (LSE: KNB), a leading patient-focused healthtech ecosystem
and provider of personalised medicinal treatments, is pleased to announce the
appointment of MHA MacIntyre Hudson ("MHA") as the Company's auditors with
immediate effect. The appointment of MHA is subject to approval by the
shareholders at the next Annual General Meeting of the Company.

 

Further to the announcement made on 2 December 2022, Jeffreys Henry LLP, the
Company's previous auditors, confirmed there are no circumstances connected
with its resignation which it considers should be brought to the attention of
members or creditors of the Company.

 

 

 

Enquiries:

 

 Kanabo Group plc                                                  via Vigo Consulting

 Avihu Tamir, Chief Executive Officer                              +44 (0)20 7390 0230

 Assaf Vardimon, Chief Financial Officer

 Peterhouse Capital Ltd (Financial Adviser and Broker)             +44 (0)20 7469 0930

 Eran Zucker/  Lucy Williams / Charles Goodfellow

 Vigo Consulting (Financial Public Relations/Investor Relations)    +44 (0)20 7390 0230

 Jeremy Garcia / Fiona Hetherington / Verity Snow

 kanabo@vigoconsulting.com

 

 

 

About Kanabo Group Plc

Founded in 2017, Kanabo Group Plc (LSE:KNB) is a patient-first HealthTech
ecosystem, focused on delivering high quality and innovative medical
treatments, via its leading-edge technology platform and disruptive product
offering.

 

The Company is a world leader in the research, development and
commercialization of regulated medicinal cannabis-derived formulations and
therapeutic inhalation devices.

 

Patient care is delivered via the company's NHS-approved online telehealth
platform offering video consultations, online prescriptions and access to
primary care services.  In January 2023, the Company successfully combined
its technological and product expertise to launch the Beta phase of its
medical cannabis business, initially for chronic pain management, under the
new Treat-It brand.

 

Kanabo Group is committed to evolving more accessible healthcare experiences
for every patient.

 

Visit www.kanabogroup.com (http://www.kanabogroup.com)  for more info.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  APPUPUAUWUPWGPM